MedPath

Childrens Cancer and Leukemia Study Group (CCLSG) ALL2004 : A Multi-Center Phase II Study in Children with Newly Diagnosed Acute Lymphoblastic Leukemia

Phase 2
Conditions
Childhood acute lymphoblastic leukemia
Registration Number
JPRN-UMIN000010488
Lead Sponsor
Childhood Cancer and Leukemia Study Group (CCLSG)
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up continuing
Sex
All
Target Recruitment
230
Inclusion Criteria

Not provided

Exclusion Criteria

1) mature B-ALL 2) Ph+ALL : After registration, stop the protocol study with information of Ph+. 3) organ dysfunction for attending protocol study. 4) pregnancy or high possibility of pregnancy and giving suck woman. 5) history of congenital or acquired immunodeficiency. 6) uncontrollable infection 7) any inappropriate status judged by physician.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Primary endpoint 1) 3 years event free survival(3y-EFS) 1.1.3y-EFS difference between Point1:MRD(-) with Point2:MRD(-) group and Point1:MRD(+) with Point2:MRD(-) group 1.2.3y- EFS improving by the salvage therapy for Point2:MRD(+) group
Secondary Outcome Measures
NameTimeMethod
Secondary endpoint 1)Severe adverse event rate in each risk- classification group. 2)Relationship between early prednisolone response and Poin1- and Point2-MRD. 3)Relationship between day15 bone marrow blast and Poin1- and Point2-MRD. 4) Relationship among Point3-,4-, 5-, 6-, 7- (at the end of protocol) MRD and relapse
© Copyright 2025. All Rights Reserved by MedPath